Hospital
Viera Hospital INC
Viera Hospital INC was paid $2.04M by Medicaid between Jan 2018 and Nov 2024, across 88 billing codes. Its largest line is 99284, emergency room visit (serious) — 29% of everything it billed.
33Billing provider infoVIERA HOSPITAL INC
MELBOURNE, FL 32940
MELBOURNE, FL 32940
33aNPI1730494816assigned 08/12/2010
33bProvider typeGeneral Acute Care Hospital
28Total paid$2.04M
24GClaims89,612
24DCodes billed88
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other General Acute Care Hospital providers in Florida
Rank by total paid#118 of 163
Median peer was paid$4.77M
This provider vs. median0.4×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official PULIO, KRISTEN controls 12+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 4,113 | $106K | |
| 2019 | 15,245 | $226K | |
| 2020 | 13,450 | $205K | |
| 2021 | 22,144 | $450K | |
| 2022 | 24,113 | $624K | |
| 2023 | 9,004 | $319K | |
| 2024incomplete | 1,543 | $105K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 29% | 6,794 | 5,966 | $590K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 26% | 6,010 | 5,520 | $526K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 15% | 3,261 | 2,813 | $305K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 4.6% | 1,140 | 1,054 | $94K |
| 80053 | Comprehensive metabolic panel | 3.9% | 7,573 | 6,150 | $80K |
| 36415 | Collection of venous blood by venipuncture | 3.1% | 5,181 | 3,908 | $63K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.7% | 1,069 | 952 | $54K |
| 82947 | 2.0% | 404 | 294 | $41K | |
| 70450 | Computed tomography, head or brain; without contrast material | 1.8% | 1,233 | 995 | $37K |
| 87430 | 1.2% | 636 | 607 | $25K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 226 | 197 | $19K |
| 87400 | <1% | 597 | 536 | $18K |
76 more codes
| 71045 | Radiologic examination, chest; single view | <1% | 2,916 | $18K |
| 87088 | <1% | 1,541 | $16K | |
| A9270 | Non-covered item or service | <1% | 7,199 | $15K |
| 81001 | <1% | 3,734 | $13K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 590 | $12K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 7,642 | $10K |
| 84484 | <1% | 1,760 | $9K | |
| 87486 | <1% | 900 | $9K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 2,723 | $8K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,864 | $7K |
| 81003 | <1% | 1,017 | $6K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 986 | $6K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 218 | $5K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 291 | $5K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 299 | $5K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,151 | $5K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,458 | $4K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 1,014 | $3K |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 18 | $2K |
| 81025 | <1% | 1,725 | $2K | |
| 93041 | <1% | 1,315 | $2K | |
| 59025 | Fetal non-stress test | <1% | 15 | $2K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 499 | $2K |
| 94760 | <1% | 431 | $2K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,040 | $2K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 809 | $2K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 16 | $2K |
| 94664 | <1% | 215 | $1K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 338 | $1K |
| 87210 | <1% | 94 | $1K | |
| 83690 | <1% | 1,553 | $772.90 | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 74 | $730.63 |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 316 | $691.65 |
| J2704 | Injection, propofol, 10 mg | <1% | 387 | $655.57 |
| 85027 | <1% | 641 | $652.80 | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 15 | $612.23 |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 30 | $565.84 |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 902 | $534.78 |
| 87581 | <1% | 900 | $451.32 | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 554 | $359.91 |
| 85610 | <1% | 639 | $359.03 | |
| 85730 | <1% | 343 | $350.13 | |
| 93975 | <1% | 28 | $242.47 | |
| 83735 | <1% | 523 | $173.29 | |
| 87186 | <1% | 192 | $170.83 | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 17 | $164.88 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 155 | $154.87 |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 40 | $147.53 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 155 | $69.60 |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 27 | $67.91 |
| 80061 | Lipid panel | <1% | 58 | $42.89 |
| 83880 | <1% | 80 | $38.98 | |
| 84703 | <1% | 392 | $32.22 | |
| 87040 | <1% | 61 | $27.84 | |
| 83605 | <1% | 205 | $7.79 | |
| 84702 | <1% | 49 | $7.68 | |
| 86900 | <1% | 128 | $6.72 | |
| 87081 | <1% | 585 | $5.18 | |
| 86850 | <1% | 17 | $2.90 | |
| 86901 | <1% | 128 | $1.38 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 0% | 62 | $0.00 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 476 | $0.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 481 | $0.00 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 0% | 54 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 46 | $0.00 |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 0% | 109 | $0.00 |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 0% | 28 | $0.00 |
| 85379 | 0% | 29 | $0.00 | |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 15 | $0.00 |
| 73562 | 0% | 13 | $0.00 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 74 | $0.00 |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 0% | 30 | $0.00 |
| 73630 | 0% | 15 | $0.00 | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 0% | 16 | $0.00 |
| 87420 | 0% | 14 | $0.00 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialPULIO, KRISTEN (SVP CFO)
| Provider | Location | Paid |
|---|---|---|
| Holmes Regional Medical Center, INC. | Melbourne, FL | $12.33M |
| Adventist Healthcare Fort Washington Medical Center INC | Ft Washington, MD | $8.63M |
| Holmes Regional Medical Center, INC | Palm Bay, FL | $7.24M |
| Hospice of Health First INC. | West Melbourne, FL | $4.13M |
| Cape Canaveral Hospital, INC. | Cocoa Beach, FL | $3.66M |
| Blackwell Physicians, LLC | Rockville, MD | $1.94M |
| Adventist Physician Services, INC. | Rockville, MD | $405K |
| Adventist Physician Services, INC. | Takoma Park, MD | $79K |
| Holmes Regional Medical Center, INC. | Melbourne, FL | $25K |
| Adventist Physician Services, INC. | Germantown, MD | $5K |
| Doctors Gi Partnership LTD | Palm Bay, FL | $932.71 |
| Cape Canaveral Hospital, INC. | Melbourne, FL | $0.00 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.